Topics:

Champions strikes deal with Concordia

Champions strikes deal with Concordia

Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.

As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.